Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

HORSHAM, Pa., and KENILWORTH, N.J., December 8, 2005 Landmark studies published today in The New England Journal of Medicine demonstrate the benefits of treatment with REMICADE (infliximab) in patients with ulcerative colitis (UC).

At week 8, in both the 54-week ACT 1 trial and the 30-week ACT 2 trial, statistically significant differences in the proportion of patients in clinical response, clinical remission, and with mucosal healing were shown in UC patients treated with REMICADE versus those receiving placebo. In particular, approximately two-thirds of UC patients treated with REMICADE achieved the primary endpoint of clinical response, defined as improvement in signs and symptoms. Moreover, more than half had mucosal healing and more than one-third were in clinical remission. Furthermore, in both ACT 1 and ACT 2, nearly one-quarter of REMICADE patients receiving corticosteroids at baseline were in remission and steroid-free by week 30. In both ACT 1 and ACT 2, a significantly greater proportion of patients treated with REMICADE compared with placebo achieved clinical response, clinical remission, and mucosal healing from week 8 through the end of each trial (week 54 in ACT 1 and week 30 in ACT 2).

A major advance in the treatment of UC, REMICADE is the first and only biologic indicated in the United States for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately-to-severely active UC who have had an inadequate response to conventional therapy. This approval was based on the 30-week data from both trials.

"These long term results highlight the benefits of REMICADE for the treatment of UC," said William J. Sandborn, MD, professor of medicine, Mayo Clinic College of Medicine, head of the Inflammatory Bowel Disease (IBD) Interest Group, director of the IBD Clinical Research Unit at Mayo Medical Center, and lead study investigator. "These data

Contact: Michael Parks
Centocor, Inc.

Page: 1 2 3 4

Related biology news :

1. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
2. Manomet report studies impact of massive turnover of timberland in New Englands Northern Forest
3. Avian flu in perspective: New England Journal article reviews spectacular findings
4. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
5. Stretching the supply of flu vaccine: Solution offered in new SLU research in New England Journal
6. News tips from the Journal of Neuroscience
7. News tips from the Journal of Neuroscience
8. News tips from the Journal of Neuroscience
9. News tips from the Journal of Neuroscience
10. Tips from the Journals of the American Society for Microbiology
11. Journalists can register now for ECCO 14 -- the European Cancer Conference

Post Your Comments:

(Date:5/14/2020)... ... May 14, 2020 , ... The ... sales representatives, found the 2019 average medical sales rep total compensation increased by ... by uncertainties amid the COVID-19 global crisis. , The MedReps 2020 Salary Survey ...
(Date:5/1/2020)... FT. LAUDERDALE, Fla. (PRWEB) , ... April 30, ... ... Commission accredited telemedicine company backed by Siemens Healthineers and several healthcare VC firms ... against COVID-19, the goal of CareDoctors.com is to enhance patient care experience by ...
(Date:4/30/2020)... , ... April 28, 2020 , ... Pebble Labs ... biggest challenges in agriculture and aquaculture with the mission of improving global food security, ... 2020 F&A Next ' Next Heroes in Food- and Ag-Tech ' virtual event, a ...
Breaking Biology News(10 mins):
(Date:5/1/2020)... ... 2020 , ... The winners of Fast Company’s 2020 World ... that are actively engaged and deeply committed to changing the world. Amongst the ... top prize in the Experimental category. , The RASTRUM™ 3D Bioprinter from Inventia ...
(Date:4/22/2020)... ... 21, 2020 , ... Aniara Diagnostica is pleased to announce ... Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening ... and cost-efficient delivery. , For Research Use Only. Not for Use ...
(Date:4/7/2020)... ... April 06, 2020 , ... ... the life sciences industry, has announced the release of at-home virtual learning resources ... priority is the health and safety of our employees as we continue to ...
(Date:4/1/2020)... ... March 31, 2020 , ... Carterra® Inc., the world ... (LJI), announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds ... the clinic as early as this summer. , La Jolla Institute for Immunology ...
Breaking Biology Technology:
Cached News: